Peter Jones

Peter Jones is the Vice President of CMC of Evox Therapeutics. Mr. Jones has more than 30 years of process development experience in the biopharmaceutical industry, building and leading cross-functional teams to support clinical and commercial development. During those years, he has led the development of manufacturing platforms and played a leadership role in the commercialization of over 16 products across the small molecule, biopharmaceutical gene, and cell therapy applications. Before joining Evox, he was Executive Director, Process Development at Autolus Therapeutics plc, where he led late-stage CMC activities for the AUTO1 (obe-cel) CD19 CAR T cell therapy program. Prior to that, Mr. Jones held several positions of increasing responsibility at Oxford Biomedica, including Senior Director, Head of Operational Strategy, Head of Technical Operations, and Head of Manufacturing Development supporting CMC-related activities for the Novartis’ CAR T cell therapy, Kymriah®, and Orchard Therapeutics’ ADA-SCID gene therapy. Mr. Jones also served 20 years in multiple leadership roles spanning from Discovery to Manufacturing at GlaxoSmithKline and Genzyme. Mr. Jones earned a BSc in Applied Biology at the University of Hertfordshire and a MSc (Eng) in Biochemical Engineering at University College, London. He is a chartered chemical engineer, Fellow of the Institution of Chemical Engineers and a Royal Academy of Engineering Visiting Professor in manufacturing of advanced therapies at Aston University in Birmingham, UK.

Peter Jones is the Vice President of CMC at Evox Therapeutics, based in Europe. With a background in Biotechnology, Peter Jones has a rich history of leadership and innovation.Peter Jones studied BSc (Hons) Applied Biology (Sandwich) at University of Hertfordshire. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.